Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Has Consensus Price Target of $365.40 According to Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned an average recommendation of “Buy” from the thirteen research firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $377.20.

A number of equities research analysts recently weighed in on KRYS shares. Citigroup upped their price objective on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Jefferies Financial Group reissued a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. TD Cowen raised their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Royal Bank Of Canada initiated coverage on shares of Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price target on the stock.

Krystal Biotech Stock Up 0.9%

Shares of KRYS stock opened at $344.96 on Friday. The firm has a market cap of $10.21 billion, a price-to-earnings ratio of 43.23 and a beta of 0.54. Krystal Biotech has a 52-week low of $158.08 and a 52-week high of $382.54. The company’s 50 day moving average is $343.58 and its 200 day moving average is $314.97.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Analysts anticipate that Krystal Biotech will post 7.48 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Krystal Biotech in the second quarter valued at about $1,554,113,000. Avoro Capital Advisors LLC grew its stake in shares of Krystal Biotech by 4.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock worth $712,226,000 after acquiring an additional 111,111 shares during the last quarter. William Blair Investment Management LLC purchased a new stake in shares of Krystal Biotech during the second quarter worth about $211,909,000. Jupiter Topco LLC acquired a new position in shares of Krystal Biotech during the second quarter valued at about $95,387,000. Finally, Bank of America Corp DE acquired a new position in shares of Krystal Biotech during the second quarter valued at about $95,308,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.